Recent advances in the treatment of narcolepsy

Current Treatment Options in Neurology

Volumn 13, Issue 5, 2011, Pages 437-457

  Hirai, Nobuhide ^a,b   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARMODAFINIL; ATOMOXETINE; CAFFEINE; CLOMIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MAZINDOL; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; OREXIN; OXYBATE SODIUM; PEMOLINE; PREDNISONE; PROTIRELIN; PROTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGITATION; ARTICLE; ATTENTION DEFICIT DISORDER; ATYPICAL DEPRESSION; BLURRED VISION; BRADYCARDIA; CATAPLEXY; CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; COMA; CONFUSION; CONSTIPATION; DAYTIME SOMNOLENCE; DIET THERAPY; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; GENE THERAPY; HALLUCINATION; HUMAN; HYPNAGOGIC HALLUCINATION; IMPOTENCE; INSOMNIA; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; NARCOLEPSY; NAUSEA; NONHUMAN; ORGASM DISORDER; ORTHOSTATIC HYPERTENSION; PARASOMNIA; PLASMAPHERESIS; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP APNEA SYNDROME; SLOW WAVE SLEEP; TACHYCARDIA; TOOTH DISEASE; TREATMENT DURATION; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 80755153154     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0137-6     Document Type: Article

References (117)

1. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol. 1994;35(6):709-16. (Pubitemid 24172171)
2. Mignot E. Genetic and familial aspects of narcolepsy. Neurology. 1998;50(2 SUPPL. 1):S16-22. (Pubitemid 28100862)
3. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol. 1997;52(1):27-78. (Pubitemid 27242520)
4. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499-511. (Pubitemid 46209316)
5. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999;22(6):757-65. (Pubitemid 29445343)
6. Nishino S, Kotorii N. Overview of management of narcolepsy. In: Goswami M, Pandi-Perumal SR, Thorpy MJ, editors, Narcolepsy, a clinical guide. New York: Springer; 2010. p. 251-65. This chapter presents an overview of narcolepsy symptoms, current treatment, and future treatment options.
7. Association AN. Stimulant medication survey. The Eye Opener. 1992;1-3.
8. Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705-11. (Pubitemid 350234749)
9. Billiard M. Narcolepsy: current treatment options and future approaches. Neuropsychiatr Dis Treat. 2008;4(3):557-66. (Pubitemid 352037835)
10. Thorpy M. Therapeutic advances in narcolepsy. Sleep Med. 2007;8(4):427-40. (Pubitemid 46706356)
11. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004;61(7-8):857-72. (Pubitemid 38659659)
12. Mitler MM, Aldrich MS, Koob GF, et al. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep. 1994;17(4):352-71. (Pubitemid 24233999)
13. Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep. 1991;14(3):218-20.
14. Simpson LL. Blood pressure and heart rate responses produced by d-amphetamine: correlation with blood levels of drug. J Pharmacol Exp Ther. 1978;205(2):366-73. (Pubitemid 8357782)
15. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst. 1960;21:704-6.
16. Parkes JD, Baraitser M, Marsden CD, et al. Natural history, symptoms and treatment of the narcoleptic syndrome. Acta Neurol Scand. 1975;52(5):337-53.
17. Guilleminault C, Carskadon M, Dement WC. On the treatment of rapid eye movement narcolepsy. Arch Neurol. 1974;30(1):90-3.
18. Passouant P, Billiard M. Narcolepsy. Rev Prat. 1976;26(27):1917-23.
19. Rogers AE, Aldrich MS, Berrios AM, et al. Compliance with stimulant medications in patients with narcolepsy. Sleep. 1997;20(1):28-33. (Pubitemid 27176317)
20. Auger RR, Goodman SH, Silber MH, et al. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. Sleep. 2005;28(6):667-72. (Pubitemid 40798707)
21. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):695-700.
22. Besset A, Tafti M, Villemin E, et al. The effects of modafinil (300 mg) on sleep, sleepiness and arousal in narcoleptic patients. Neurophysiol Clin. 1993;23(1):47-60. (Pubitemid 23051851)
23. Boivin DB, Montplaisir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol. 1993;16(1):46-53. (Pubitemid 23028497)
24. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54(5):1166-75.
25. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444-51. (Pubitemid 27368880)
26. Hermant JF, Rambert FA, Duteil J. Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration. Psychopharmacology (Berl). 1991;103(1):28-32.
27. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl). 1996;126(4):286-92. (Pubitemid 26276699)
28. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther. 1997;283(2):757-69. (Pubitemid 27514637)
29. Nishino S, Okuro M. Armodafinil for excessive daytime sleepiness. Drugs Today (Barc). 2008;44(6):395-414.
30. Wong YN, Simcoe D, Hartman LN, et al. A doubleblind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999;39(1):30-40. (Pubitemid 29053150)
31. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol. 1999;39(3):281-8. (Pubitemid 29148551)
32. Robertson Jr P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37. (Pubitemid 36188553)
33. Gonzalez MA, Pentikis HS, Anderl N, et al. Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther. 2002;40(4):175-84. (Pubitemid 34296385)
34. Iijima S, Sugita Y, Teshima Y, et al. Therapeutic effects of mazindol on narcolepsy. Sleep. 1986;9(1 Pt 2):265-8. (Pubitemid 18008507)
35. Nishino S, Mao J, Sampathkumaran R, et al. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online. 1998;1(1):49-61.
36. Rye DB, Dihenia B, Bliwise DL. Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion. Depress Anxiety. 1998;7(2):92-5. (Pubitemid 28235122)
37. Thorpy MJ, Snyder M, Aloe FS, et al. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep. 1992;15(3):212-6.
38. Scrima L, Hartman PG, Johnson Jr FH, et al. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatr. 1989;26(4):331-43. (Pubitemid 19198218)
39. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6(1):1-6. (Pubitemid 9149901)
40. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med. 1992;156(4):380-4.
41. Mack RB. Love potion number 8 1/2. Gammahydroxybutyrate poisoning. N C Med J. 1993;54(5):232-3.
42. Wong CG, Gibson KM, Snead 3rd OC. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci. 2004;25(1):29-34. (Pubitemid 38076954)
43. Nicholson KL, Balster RL. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001;63(1):1-22. (Pubitemid 32288730)
44. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26(1):31-5.
45. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119-23.
46. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42-9.
47. Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391-7.
48. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med. 2009;10(4):490-3.
49. Sansa G, Iranzo A, Santamaria J. Obstructive sleep apnea in narcolepsy. Sleep Med. 2010;11(1):93-5.
50. Feldman NT. Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing. Sleep Breath. 2010;14(1):77-9.
51. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med. 1998;31(6):723-8. (Pubitemid 28252628)
52. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. 2003;17(12):1691-3.
53. Nishino S. Modes of action of drugs related to narcolepsy: pharmacology of wake-promoting compounds and anticataplectics. In: Goswami M, Pandi-Perumal SR, and Thorpy MJ, editors. Narcolepsy a clinical guide. New York: Springer; 2010:267-86. This chapter presents a comprehensive and updated review of the mechanisms of the therapeutic compounds for narcolepsy.
54. Baldessarini RJ. How do antidepressants work? In: Davis JM, Mass JW, editors. The affective disorders. Washington DC: American Psychiatric Press; 1983. p. 243-60.
55. Langdon N, Shindler J, Parkes JD, et al. Fluoxetine in the treatment of cataplexy. Sleep. 1986;9(2):371-3. (Pubitemid 18020428)
56. Montplaisir J, Godbout R. Serotoninergic reuptake mechanisms in the control of cataplexy. Sleep. 1986;9(1 Pt 2):280-4. (Pubitemid 18008510)
57. Schrader H, Kayed K, Bendixen Markset AC, Treidene HE. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand. 1986;74(4):297-303. (Pubitemid 17198888)
58. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl). 1993;113(1):76-82. (Pubitemid 23341049)
59. Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep. 1993;16(8):706-12. (Pubitemid 24054961)
60. Takahashi S. The action of tricyclics (alone or in combination with methylphenidate) upon several symptoms of narcolepsy. In: Guilleminault C, Dement WC, Passouant P, editors. Narcolepsy. New York: Spectrum Publication; 1976. p. 625-38.
61. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep. 1986;9(1 Pt 2):285-9. (Pubitemid 18008511)
62. Lin JS. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev. 2000;4(5):471-503.
63. Steininger TL, Alam MN, Gong H, et al. Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res. 1999;840(1-2):138-47. (Pubitemid 29434833)
64. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715-30. (Pubitemid 36694779)
65. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A. 2001;98(17):9965-70.
66. Kanbayashi T, Kodama T, Kondo H, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep. 2009;32(2):181-7.
67. Nishino S, Sakurai E, Nevsimalova S, et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep. 2009;32(2):175-80.
68. Tedford CE, Edgar DM, Seidel WF, et al. Effects of a novel, selective, and potent histamine H3 receptor antagonist, GT-2331, on rat sleep-wakefulness and canine cataplexy [abstract]. Society for Neuroscience. 1999;25:460.3:32.
69. Lin JS, Sakai K, Vanni-Mercier G, et al. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res. 1990;523(2):325-30. (Pubitemid 20230168)
70. Shiba T, Fujiki N, Wisor JP, et al. Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narcoleptic mice. Sleep. 2004;27(SUPPL.ement):A241-2.
71. Parmentier R, Anaclet C, Guhennec C, et al. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol. 2007;73(8):1157-71. (Pubitemid 46413178)
72. Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci. 1997;17(16):6401-8. (Pubitemid 27329912)
73. Heuer H, Schafer MK, O'Donnell D, et al. Expression of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats. J Comp Neurol. 2000;428(2):319-36.
74. Sharp T, Bennett GW, Marsden CA. Thyrotrophinreleasing hormone analogues increase dopamine release from slices of rat brain. J Neurochem. 1982;39(6):1763-6. (Pubitemid 13184160)
75. Keller HH, Bartholini G, Pletscher A. Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature. 1974;248(448):528-9.
76. Vogel HP, Benkert O, Illig R, et al. Psychoendocrinological and therapeutic effects of TRH in depression. Acta Psychiatr Scand. 1977;56(3):223-32. (Pubitemid 8171884)
77. Bunevicius R, Matulevicius V. Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study. Psychoneuroendocrinology. 1993;18(5-6):445-9. (Pubitemid 23214783)
78. Broberger C, McCormick DA. Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci. 2005;25(7):1664-73. (Pubitemid 40279271)
79. Hara J, Gerashchenko D, Wisor JP, et al. Thyrotropinreleasing hormone increases behavioral arousal through modulation of hypocretin/orexin neurons. J Neurosci. 2009;29(12):3705-14.
80. Gonzalez JA, Horjales-Araujo E, Fugger L, et al. Stimulation of orexin/hypocretin neurones by thyrotropin-releasing hormone. J Physiol. 2009;587(Pt 6):1179-86.
81. Kotorii N, Okuro M, Takahashi S, et al. Effects of thyrotropin-releasing hormone analogs in the narcoleptic model mouse. Sleep. 2009;32(SUPPL.ement): A241.
82. Parmentier R, Kolbaev S, Klyuch BP, et al. Excitation of histaminergic tuberomamillary neurons by thyrotropin-releasing hormone. J Neurosci. 2009;29(14):4471-83.
83. Schomburg L, Turwitt S, Prescher G, et al. Human TRH-degrading ectoenzyme cDNA cloning, functional expression, genomic structure and chromosomal assignment. Eur J Biochem. 1999;265(1):415-22. (Pubitemid 29466052)
84. Xu YL, Reinscheid RK, Huitron-Resendiz S, et al. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron. 2004;43(4):487-97. (Pubitemid 39094676)
85. Porrino LJ, Daunais JB, Rogers GA, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol. 2005;3(9):e299.
86. Ehrman LA, Williams MT, Schaefer TL, et al. Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice. Genes Brain Behav. 2006;5(7):540-51. (Pubitemid 44423511)
87. Okura M, Riehl J, Mignot E, et al. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology. 2000;23(5):528-38.
88. Scrima L, Hartman PG, Johnson Jr FH, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990;13(6):479-90.
89. Huang YS, Guilleminault C. Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol. 2009;41(1):9-16.
90. Krogsgaard-Larsen P, Frolund B, Liljefors T, et al. GABA (A) agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol. 2004;68(8):1573-80. (Pubitemid 39286462)
91. Kastin AJ, Akerstrom V. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther. 1999;289(1):219-23. (Pubitemid 29156032)
92. Yoshida Y, Fujiki N, Maki RA, et al. Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett. 2003;346(3):182-6. (Pubitemid 36829291)
93. Fujiki N, Yoshida Y, Ripley B, et al. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep. 2003;26(8):953-9. (Pubitemid 39619754)
94. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, et al. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med. 2004;18(4):586-8. (Pubitemid 39107553)
95. Mieda M, Willie JT, Hara J, et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A. 2004;101(13):4649-54. (Pubitemid 38437465)
96. Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis. 2001;8(3):525-34. (Pubitemid 32566142)
97. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-76. (Pubitemid 29380571)
98. Hanson LR, Martinez PM, Taheri S, et al. Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: a new strategy for the treatment of narcolepsy. Drug Deliv Tech. 2004;4(4):66-71.
99. Deadwyler SA, Porrino L, Siegel JM, et al. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007;27(52):14239-47.
100. Liu M, Thankachan S, Kaur S, et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci. 2008;28(7):1382-93.
101. Arias-Carrión O, Murillo-Rodriguez E, Xu M, et al. Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep. 2004;27(8):1465-70. (Pubitemid 40041613)
102. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000;27(3):469-74.
103. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59(10):1553-62.
104. Neurobiology BA. Better cells for brain repair. Nature. 1993;362(6419):414-5.
105. Asahi S, Egashira S, Matsuda M, et al. Structure-activity relationship studies on the novel neuropeptide orexin. Vol. 1999. In: Fujii N, editors. The Japanese Peptide Society; 2000. p. 37-40.
106. Darker JG, Porter RA, Eggleston DS, et al. Structureactivity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg Med Chem Lett. 2001;11(5):737-40. (Pubitemid 32187967)
107. Croston GE, Olsson R, Currier EA, et al. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino) ethyl) isochroman-1-one (AC-7954). J Med Chem. 2002;45(23):4950-3. (Pubitemid 35278689)
108. Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. Life Sci. 2003;73(6):663-78. (Pubitemid 36703261)
109. Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A. 2002;99(10):7136-41. (Pubitemid 34526268)
110. Hecht M, Lin L, Kushida CA, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin- deficiency narcolepsy. Sleep. 2003;26(7):809-10. (Pubitemid 39610624)
111. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res. 2003;12(4):347-8. (Pubitemid 38010443)
112. Dauvilliers Y, Carlander B, River F, et al. IVIG treatment in narcolepsy: report on two new cases. J Sleep Res. 2004;13 SUPPL. 1:167.
113. Zuberi SM, Mignot E, Ling L, et al. Variable response to intravenous immunoglobulin therapy in childhood narcolepsy. J Sleep Res. 2004;13 SUPPL. 1:828.
114. Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol. 2007;254(11):1607-8. (Pubitemid 350159905)
115. Taheri S, Krempetz M, Jackson M, et al. Investigation of the autoimmune basis of narcolepsy using western blot analysis of lateral hypothalamus protein extract with serum and cerebrospinal fluid. Sleep. 2003;26(SUPPL.):A285.
116. Chen W, Black J, Call P, et al. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol. 2005;58(3):489-90. (Pubitemid 41266641)
117. Aran A, Lin L, Nevsimalova S, et al. Elevated antistreptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32(8):979-83.